Facts About Kinavet

Kinavet-CA1® belongs to the family of drugs called tyrosine kinase receptor inhibitors, which over the last decade have helped to revolutionize the management of certain human cancers and have now been successfully developed for veterinary medicine. This targeted therapy inhibits cellular signaling pathways that regulate key cell functions and survival.

The main cellular targets of Kinavet-CA1® are mast cells. Kinavet-CA1® has been designed specifically to target mast cells and is approved for the treatment of non-resectable canine mast cell tumors*. Kinavet-CA1® represents cutting-edge technology in the treatment of cancer through its ability to target those cells or signaling pathways responsible for tumor growth. By targeting mast cells it therefore works directly at the origin of the tumor.

Kinavet-CA1® is a targeted therapy. Kinavet-CA1® is optimized to target just a few key tyrosine kinases that are implicated in various diseases, while not inhibiting, at therapeutic doses, those tyrosine kinases attributed to possible toxicity. This permits Kinavet-CA1® to be administered at higher doses for a more potent therapeutic effect, while maintaining an acceptable level of tolerability and better safety profile compared to multi-targeting drugs or traditional chemotherapies (for example, cytotoxic drugs).

Kinavet-CA1® is not a chemotherapy drug. Several important distinctions exist including that unlike cytotoxic chemotherapies, which inhibit replication of a great many cells including healthy and useful ones, Kinavet-CA1® is a targeted therapy that limits collateral damage to healthy tissue.

Kinavet-CA1® is easy to use. Kinavet-CA1® is delivered orally in tablet form and can be administered everyday directly by the owner at their home.

Kinavet-CA1® is an effective treatment of mast cell tumors. Clinical trials of Kinavet-CA1® have scientifically proven it to be a valuable anti-cancer treatment with possible long term benefits. At least 50% of dogs treated with Kinavet-CA1® had their tumor half in size during the first 6 months.

Kinavet-CA1® is a safe treatment of mast cell tumors. Kinavet-CA1® is generally well tolerated with medically manageable side-effects.

Kinavet-CA1® tablets are indicated for the treatment of recurrent (post?�?surgery) or nonresectable Grade II or III cutaneous mast cell tumors in dogs that have not previously received radiotherapy and/or chemotherapy except corticosteroids. Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal Law to use this product other than as directed in the labeling.